Literature DB >> 30134124

Applications of Immunopharmacogenomics: Predicting, Preventing, and Understanding Immune-Mediated Adverse Drug Reactions.

Jason H Karnes1,2,3, Matthew A Miller1, Katie D White4, Katherine C Konvinse5,6, Rebecca K Pavlos7,8, Alec J Redwood8, Jonathan G Peter9,10, Rannakoe Lehloenya9, Simon A Mallal4,5,8, Elizabeth J Phillips4,5,8.   

Abstract

Adverse drug reactions (ADRs) are a significant health care burden. Immune-mediated adverse drug reactions (IM-ADRs) are responsible for one-fifth of ADRs but contribute a disproportionately high amount of that burden due to their severity. Variation in human leukocyte antigen ( HLA) genes has emerged as a potential preprescription screening strategy for the prevention of previously unpredictable IM-ADRs. Immunopharmacogenomics combines the disciplines of immunogenomics and pharmacogenomics and focuses on the effects of immune-specific variation on drug disposition and IM-ADRs. In this review, we present the latest evidence for HLA associations with IM-ADRs, ongoing research into biological mechanisms of IM-ADRs, and the translation of clinical actionable biomarkers for IM-ADRs, with a focus on T cell-mediated ADRs.

Entities:  

Keywords:  Stevens-Johnson syndrome; adverse drug reaction; human leukocyte antigen; immunopharmacogenomics; pharmacogenomics; toxic epidermal necrolysis

Mesh：

Substances：

Year:  2018        PMID： 30134124      PMCID： PMC6409210          DOI： 10.1146/annurev-pharmtox-010818-021818

Source DB:  PubMed          Journal:  Annu Rev Pharmacol Toxicol        ISSN： 0362-1642            Impact factor:   13.820


  139 in total

1.  SCORTEN: a severity-of-illness score for toxic epidermal necrolysis.

Authors:  S Bastuji-Garin; N Fouchard; M Bertocchi; J C Roujeau; J Revuz; P Wolkenstein
Journal:  J Invest Dermatol       Date:  2000-08       Impact factor: 8.551

Review 2.  Pathogenesis of drug-induced exanthems.

Authors:  W Pichler; N Yawalkar; S Schmid; A Helbling
Journal:  Allergy       Date:  2002-10       Impact factor: 13.146

3.  Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States.

Authors:  George Ostapowicz; Robert J Fontana; Frank V Schiødt; Anne Larson; Timothy J Davern; Steven H B Han; Timothy M McCashland; A Obaid Shakil; J Eileen Hay; Linda Hynan; Jeffrey S Crippin; Andres T Blei; Grace Samuel; Joan Reisch; William M Lee
Journal:  Ann Intern Med       Date:  2002-12-17       Impact factor: 25.391

4.  Anticonvulsant-induced toxic epidermal necrolysis: monitoring the immunologic response.

Authors:  L Leyva; M J Torres; S Posadas; M Blanca; G Besso; F O'Valle; R G del Moral; L F Santamaría; C Juárez
Journal:  J Allergy Clin Immunol       Date:  2000-01       Impact factor: 10.793

5.  Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir.

Authors:  S Mallal; D Nolan; C Witt; G Masel; A M Martin; C Moore; D Sayer; A Castley; C Mamotte; D Maxwell; I James; F T Christiansen
Journal:  Lancet       Date:  2002-03-02       Impact factor: 79.321

6.  HLA association of amoxicillin-clavulanate--induced hepatitis.

Authors:  M L Hautekeete; Y Horsmans; C Van Waeyenberge; C Demanet; J Henrion; L Verbist; R Brenard; C Sempoux; P P Michielsen; P S Yap; J Rahier; A P Geubel
Journal:  Gastroenterology       Date:  1999-11       Impact factor: 22.682

7.  Toxic epidermal necrolysis and Stevens-Johnson syndrome: does early withdrawal of causative drugs decrease the risk of death?

Authors:  I Garcia-Doval; L LeCleach; H Bocquet; X L Otero; J C Roujeau
Journal:  Arch Dermatol       Date:  2000-03

8.  Genetic variations in HLA-B region and hypersensitivity reactions to abacavir.

Authors:  Seth Hetherington; Arlene R Hughes; Michael Mosteller; Denise Shortino; Katherine L Baker; William Spreen; Eric Lai; Kirstie Davies; Abigail Handley; David J Dow; Mary E Fling; Michael Stocum; Clive Bowman; Linda M Thurmond; Allen D Roses
Journal:  Lancet       Date:  2002-03-30       Impact factor: 79.321

9.  Co-amoxiclav jaundice: clinical and histological features and HLA class II association.

Authors:  J O'Donohue; K A Oien; P Donaldson; J Underhill; M Clare; R N MacSween; P R Mills
Journal:  Gut       Date:  2000-11       Impact factor: 23.059

10.  Clonotype tracking of TCR repertoires during chronic virus infections.

Authors:  George B Cohen; Sabina A Islam; Miriam S Noble; Christina Lau; Christian Brander; Marcus A Altfeld; Eric S Rosenberg; Jörn E Schmitz; Thomas O Cameron; Spyros A Kalams
Journal:  Virology       Date:  2002-12-20       Impact factor: 3.616
View more
  16 in total

1.  Pharmacogenetics to prevent heparin-induced thrombocytopenia: what do we know?

Authors:  Jason H Karnes
Journal:  Pharmacogenomics       Date:  2018-11-06       Impact factor: 2.533

Review 2.  Immune-mediated adverse reactions to vaccines.

Authors:  Cosby A Stone; Christine R F Rukasin; Thomas M Beachkofsky; Elizabeth J Phillips
Journal:  Br J Clin Pharmacol       Date:  2019-11-05       Impact factor: 4.335

Review 3.  Drug hypersensitivity in HIV infection.

Authors:  Jonny Peter; Phuti Choshi; Rannakoe J Lehloenya
Journal:  Curr Opin Allergy Clin Immunol       Date:  2019-08

4.  The Immunogenetics of Cutaneous Drug Reactions.

Authors:  Neda Khalili
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 2.622

5.  Concordance between predicted HLA type using next generation sequencing data generated for non-HLA purposes and clinical HLA type.

Authors:  Ann M Moyer; Brian Dukek; Patti Duellman; Brittany Schneider; Laurie Wakefield; Jennifer M Skierka; Rajeswari Avula; Aditya V Bhagwate; Krishna R Kalari; Justin D Kreuter; Matthew P Goetz; Judy C Boughey; John L Black; Manish J Gandhi
Journal:  Hum Immunol       Date:  2020-06-13       Impact factor: 2.850

6.  Delabeling Delayed Drug Hypersensitivity: How Far Can You Safely Go?

Authors:  Rannakoe J Lehloenya; Jonny G Peter; Ana Copascu; Jason A Trubiano; Elizabeth J Phillips
Journal:  J Allergy Clin Immunol Pract       Date:  2020-10

Review 7.  Genophenotypic Factors and Pharmacogenomics in Adverse Drug Reactions.

Authors:  Ramón Cacabelos; Vinogran Naidoo; Lola Corzo; Natalia Cacabelos; Juan C Carril
Journal:  Int J Mol Sci       Date:  2021-12-10       Impact factor: 5.923

Review 8.  Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and HLA-B Genotypes and Phenytoin Dosing: 2020 Update.

Authors:  Jason H Karnes; Allan E Rettie; Andrew A Somogyi; Rachel Huddart; Alison E Fohner; Christine M Formea; Ming Ta Michael Lee; Adrian Llerena; Michelle Whirl-Carrillo; Teri E Klein; Elizabeth J Phillips; Scott Mintzer; Andrea Gaedigk; Kelly E Caudle; John T Callaghan
Journal:  Clin Pharmacol Ther       Date:  2020-09-06       Impact factor: 6.875

9.  Clinical Utility of Pharmacogenomic Data Collected by a Health-System Biobank to Predict and Prevent Adverse Drug Events.

Authors:  Sonam N Shah; Roseann S Gammal; Mary G Amato; Maryam Alobaidly; Dariel Delos Reyes; Sarah Hasan; Diane L Seger; Joel B Krier; David W Bates
Journal:  Drug Saf       Date:  2021-02-23       Impact factor: 5.606

Review 10.  Genetic Determinants in HLA and Cytochrome P450 Genes in the Risk of Aromatic Antiepileptic-Induced Severe Cutaneous Adverse Reactions.

Authors:  Ali Fadhel Ahmed; Chonlaphat Sukasem; Majeed Arsheed Sabbah; Nur Fadhlina Musa; Dzul Azri Mohamed Noor; Nur Aizati Athirah Daud
Journal:  J Pers Med       Date:  2021-05-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.